Kopp Development v. Metrasens: MRI Safety Patent Settled After 1,362 Days
Kopp Development Inc. filed a patent infringement action against Metrasens Inc. in Ohio’s Northern District, asserting US7489128B2 over the Ferroguard MRI safety detection system. The case closed with prejudice after 1,362 days — nearly four years — consistent with a confidential settlement between the parties.
MRI Ferromagnetic Detection IP Dispute Ends in Confidential Settlement
On 21 June 2021, Kopp Development Inc. filed a patent infringement action against Metrasens Inc. in the U.S. District Court for the Northern District of Ohio before Judge Pamela A. Barker. The suit centred on US7489128B2, a patent covering MRI safety equipment — specifically ferromagnetic detection technology — which Kopp alleged was infringed by Metrasens’ Ferroguard system, a market-leading ferromagnetic detection product used to protect MRI suites from projectile incidents.
The case concluded on 14 March 2025 via a joint stipulation of dismissal with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The parties simultaneously requested that the court retain jurisdiction to enforce the terms of a settlement reached between them. Dismissal with prejudice means Kopp Development cannot re-file the same infringement claims against Metrasens — the litigation is permanently resolved on these facts. The court’s retained jurisdiction provision suggests financial or licensing terms were agreed upon privately.
The 1,362-day duration suggests the parties litigated substantively before reaching terms, potentially through claim construction proceedings, discovery, or pre-trial motions. The public record does not disclose the financial or licensing terms of the settlement, which is typical for stipulated dismissals of this kind. What remains unknown is whether Metrasens obtained a licence to the asserted patent, agreed to design-around obligations, or reached a different commercial resolution — the strategic significance will depend heavily on those undisclosed terms.
Filing to Dismissed with Prejudice in 1362 days
1,362 days — approximately 3.7 years, above the median for patent infringement cases in the Northern District of Ohio
Dismissed with prejudice: what the stipulated settlement means for both parties
Rule 41(a)(1)(A)(ii) dismissal with prejudice explained
A stipulated dismissal under Rule 41(a)(1)(A)(ii) requires the consent of all parties and carries the legal weight of a final adjudication when filed with prejudice. ‘With prejudice’ bars Kopp Development from re-asserting the same patent claims against Metrasens on the same accused products. The court’s retained jurisdiction is a standard mechanism to enforce any financial, licensing, or behavioural obligations agreed in the settlement without requiring a new lawsuit.
Permanent bar on re-filingKopp Development exits with a confidential resolution — and a permanent bar
By agreeing to dismissal with prejudice, Kopp Development cannot pursue Metrasens again on US7489128B2 for the accused Ferroguard conduct. In exchange, the public record implies Kopp received some form of consideration — whether a lump-sum payment, ongoing royalties, or a licensing arrangement. The patent itself remains valid and enforceable against third parties; only Metrasens gains finality from this specific dismissal.
Settlement value undisclosedMetrasens buys certainty — at an undisclosed price
Metrasens secured a permanent resolution of the infringement claims over its Ferroguard system. With prejudice dismissal means no resurrection of these specific claims, giving Metrasens commercial certainty to continue operating. The court’s retained jurisdiction clause, however, means Metrasens remains subject to judicial oversight for compliance with whatever terms were privately agreed. The absence of an invalidity ruling leaves US7489128B2 intact as a potential risk for other MRI safety product competitors.
Ferroguard claims permanently resolvedUS7489128B2 remains a live threat for the MRI safety sector
Because the case settled without any court ruling on validity or infringement, US7489128B2 survives fully enforceable. Competitors developing or supplying ferromagnetic detection equipment for MRI environments cannot draw comfort from this outcome — the patent’s scope was never adjudicated. Any company operating in the MRI safety equipment space should treat this patent as an active enforcement risk and conduct freedom-to-operate analysis against their product architecture.
Patent validity unchallengedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Kopp Development Inc. | Company | MRI safety IP licensor — holder of US7489128B2 covering ferromagnetic detectionSearch in Eureka ↗ |
| Defendant | Metrasens, Inc. | Company | Metrasens Inc. — developer and supplier of the Ferroguard MRI ferromagnetic detection systemSearch in Eureka ↗ |
| Plaintiff counsel | Brian T. Winchester | Attorney | Counsel for Kopp Development Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert R. Terbrack , Jr. | Attorney | Counsel for Kopp Development Inc.Search in Eureka ↗ |
| Plaintiff law firm | McNeal, Schick, Archibald & Biro | Law Firm | Representing Kopp Development Inc.Search in Eureka ↗ |
| Defendant counsel | David E. Goddard | Attorney | Counsel for Metrasens, Inc.Search in Eureka ↗ |
| Defendant counsel | Edmund L. Wagoner , III | Attorney | Counsel for Metrasens, Inc.Search in Eureka ↗ |
| Defendant counsel | James C. Carpenter | Attorney | Counsel for Metrasens, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael Thomas Smith | Attorney | Counsel for Metrasens, Inc.Search in Eureka ↗ |
| Defendant counsel | Vincent I. Holzhall | Attorney | Counsel for Metrasens, Inc.Search in Eureka ↗ |
| Defendant law firm | Birch, Stewart, Kolasch & Birch | Law Firm | Representing Metrasens, Inc.Search in Eureka ↗ |
| Defendant law firm | Goddard Law – Bridgeport | Law Firm | Representing Metrasens, Inc.Search in Eureka ↗ |
| Defendant law firm | Hansberry & Wagoner – Morgantown | Law Firm | Representing Metrasens, Inc.Search in Eureka ↗ |
| Defendant law firm | Steptoe & Johnson – Columbus | Law Firm | Representing Metrasens, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Pamela A. Barker | Judge | Ohio Northern District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulation invokes Rule 41(a)(1)(A)(ii), requiring mutual consent — distinguishing this from a unilateral plaintiff withdrawal. The ‘with prejudice’ designation is the operative legal consequence: it functions as a final judgment on the merits for preclusion purposes, permanently barring Kopp from re-litigating these infringement claims against Metrasens on the Ferroguard system. The explicit request for retained jurisdiction is legally significant — it converts the settlement into an enforceable court order, giving both parties judicial recourse for any post-dismissal breach without initiating a new action.
US7489128B2 — MRI ferromagnetic detection and safety equipment
US7489128B2 (application number US10/095543) covers technology for detecting ferromagnetic objects in proximity to MRI environments — a critical safety function in clinical and research settings where unsecured metallic objects can become lethal projectiles. The patent addresses the engineering challenge of reliably identifying ferromagnetic threats before they enter the high-field magnetic zone of an MRI scanner. Its application date places the invention in a period of rapid MRI suite proliferation and growing clinical safety regulation.
In the MRI safety equipment market, ferromagnetic detection technology sits at the intersection of patient safety compliance, hospital liability, and equipment procurement decisions. Metrasens’ Ferroguard system is among the most widely deployed products in this category globally, making US7489128B2 commercially significant IP. Any competitor offering fixed-point or portal-style ferromagnetic detection for MRI zones should consider this patent a primary landscape reference — its enforceability is confirmed by the willingness to litigate for nearly four years and the absence of any invalidation ruling.
Should your MRI safety product team run an FTO against US7489128B2?
If your organisation develops, manufactures, or sells ferromagnetic detection equipment for MRI suites — including fixed sensors, portal detectors, or integrated MRI zone-management systems — US7489128B2 warrants direct FTO scrutiny. This case confirms that Kopp Development actively enforces the patent in U.S. federal court, and the settlement with Metrasens provides no safe harbour for third parties. Hospitals and healthcare systems procuring such equipment also face potential downstream exposure if a supplier lacks a licence.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US7489128B2 against your specific product architecture — identifying independent claims, dependent claim scope, and prior art that may support design-around or invalidity arguments. Given that no court has construed this patent’s claims, proactive FTO analysis is the most defensible posture for any team operating in the MRI safety equipment space. Eureka can also surface related family members and continuation risk across jurisdictions.
Run a freedom-to-operate analysis on US7489128B2 to assess your product’s exposure
Run FTO in Eureka →Similar MRI safety and medical device patent infringement cases
Explore comparable patent infringement disputes involving MRI safety and ferromagnetic detection technology filed in U.S. district courts.
What this case signals for the MRI safety equipment IP landscape
A nearly four-year litigation ending in confidential settlement leaves US7489128B2 fully intact — and the MRI safety sector on notice.
Settlement without invalidity ruling keeps patent risk live for all competitors
Because no court adjudicated the validity or scope of US7489128B2, every manufacturer of ferromagnetic detection systems for MRI suites faces the same enforcement exposure that Metrasens just resolved privately. The patent’s claims were never narrowed or invalidated — meaning Kopp Development retains full enforcement rights against the broader market.
Court-retained jurisdiction signals structured settlement obligations
The parties’ request for the Northern District of Ohio to retain jurisdiction is a strong indicator that the settlement includes ongoing obligations — likely royalty payments, milestones, or licensing compliance terms. This is not a clean exit; it is a supervised commercial arrangement, and breach of those terms could trigger rapid judicial enforcement without new litigation.
Kopp v Metrasens — key questions answered
The case was dismissed with prejudice on 14 March 2025 pursuant to a joint stipulation under Federal Rule of Civil Procedure 41(a)(1)(A)(ii). The parties reached a settlement, and the Northern District of Ohio court retained jurisdiction to enforce its terms. No public ruling on patent validity or infringement was issued.
Kopp Development asserted US7489128B2 (application number US10/095543), a patent covering MRI safety ferromagnetic detection technology. The accused product was Metrasens’ Ferroguard system, a commercially deployed ferromagnetic detection platform used in MRI suite environments.
No. A dismissal with prejudice under Rule 41(a)(1)(A)(ii) resolves the claims between these specific parties only — it does not constitute a ruling on patent validity or claim scope. US7489128B2 remains fully enforceable against third parties. No court has adjudicated or narrowed its claims.
The parties jointly requested that the Northern District of Ohio retain jurisdiction to enforce the settlement terms. This is a standard mechanism when a settlement involves ongoing obligations — such as royalty payments or licensing compliance — allowing either party to seek judicial enforcement for any breach without filing a new lawsuit.
The case ran for 1,362 days (approximately 3.7 years) from filing on 21 June 2021 to closure on 14 March 2025. This duration is consistent with substantive litigation activity — potentially including claim construction proceedings, fact discovery, and expert work — before the parties reached a confidential settlement. It suggests the matter was not resolved at an early stage.
PatSnap Eureka searches patents and litigation data to answer instantly.